Instead, the AAO-CRC group showed lipid modifying agents (n=21,898, 6.9%) and angiotensin-converting enzyme inhibitors (n=16,292, 5.1%) as the top 2 most used medication classes. The gene discussed is ACE; the disease is colorectal carcinoma.